index,Regulator Name,Regulator Type,Regulator Subtype,Regulator HGNC Symbol,Regulator Database,Regulator ID,Regulator Compartment,Regulator Compartment ID,Regulated Name,Regulated Type,Regulated Subtype,Regulated HGNC Symbol,Regulated Database,Regulated ID,Regulated Compartment,Regulated Compartment ID,Sign,Connection Type,Mechanism,Site,Cell Line,Cell Type,Tissue Type,Organism,Unnamed: 0,Score,Source,Statements,Paper IDs,Evidence Score,Match Score,Kind Score,Epistemic Value,Total Score
14,braf,protein,,braf,uniprot,p00745,cytoplasm,go:0005886,kras,protein,,kras,uniprot,p00747,cytoplasm,go:0005886,positive,d,expression,cytoplasm,,b-cell,,human,['49'],nan,nan,"in order to identify the transcriptional profiles related to braf, nras and kras mutations in primary tumors, we used microarray technology to investigate a large number (n = 142) of the samples analyzed by ngs. assuming that alterations in a limited number of myeloma cells do not appreciably affect gene expression, we arbitrarily chose a lower vaf cut-off value of 20% for the supervised analysis of 60 wild-type and 68 mutated patients. they differentially expressed 86 genes (18 of which emerged at the highest stringency level) (supplementary table 4a): 27 up- and 59 down-regulated in the mutated cases. interestingly, functional enrichment analysis revealed the involvement of a statistically significant fraction of modulated transcripts in mapk signalling (prkd2, spred2, mapkapk2, cd300a, arl6ip5, dusp6, ppm1l, grb2, lamtor3, spred1, lyn, edn1, rasgrp1 and acvr1b) at both biological process (go:0000165, q-value=3.29e-03) and pathway level (198779 wikipathway, q-value=1.33e-02) (supplementary table 4b).",pmc4695180,1,10,11,1,21
96,"mek1,2",protein,,mapk1,uniprot,p00164,cytoplasm,go:0005739,"erk1,2",protein,,mapk3,uniprot,q05207,cytoplasm,go:0005739,negative,d,inhibition,,eras,fibroblast,,rat,['10'],nan,nan,"here, we have used transformed rat embryo fibroblasts expressing e1aad5 and cha-ras oncogenes (eras cells) as a model to study a role of mek/erk pathway in regulation of autophagy, which is involved in the maintenance of viability and implementation of senescence program. senescence was induced by treatment with hdac inhibitor sodium butyrate (nabut, 4 mm). mek1,2 inhibitor pd0325901 (pd, 1 μm) was used for long-term inhibition of mek/erk pathway. the treatment of eras cells with pd0325901 leads to a complete cessation of erk1,2 phosphoryla-tion that persists for 2-120 h as evidenced by western-blot analysis (fig. 1a).",pmc5723691,1,10,11,1,21
138,pi3k,protein,,pik3ca,uniprot,q05234,plasma membrane,go:0005886,src,protein,,src,uniprot,q05234,plasma membrane,go:0005886,negative,d,inhibition,,,,,human,['115'],nan,nan,a reduction in pi3k pathway signaling correlates with sensitivity to the combined inhibition of src and the mapk pathway,pmc5833015,1,10,11,1,21
10,braf,protein,,braf,uniprot,p00398,plasma membrane,go:0005886,mek,protein,,mek1,uniprot,q03839,plasma membrane,go:0005886,positive,d,phosphorylation,,,b-cell,,vein,['174'],nan,nan,"while braf inhibitors of both classes stimulate the formation of braf-craf dimers [89,138], type-ii inhibitors are considerably less efficient than type-i inhibitors in stimulating the phosphorylation of downstream targets, i.e., of mek kinases and, henceforth, in activating the mapk pathway. among the possible explanations of this phenomenon, the one that is getting progressively increasing credit is that braf molecules locked in the dfg-out conformation by type-ii inhibitors have poor efficiency in transactivating the kinase activity of the partner protomer [48,135,138,139]. interestingly, type-ii kinase inhibitors are directed toward the most divergent regions among the various kinases, thus having the additional potential advantage of exerting a highly selective, target-specific action. based on previous considerations, type-ii inhibitors should have greater potential than type-i inhibitors in maximizing braf inhibition as single agents or in combined therapies for melanoma treatment. unfortunately, first generation type-ii inhibitors did not hold up to the promises, at least for melanoma treatment.",pmc6472057,1,10,9,1,19
11,braf,protein,,braf,uniprot,p00722,plasma membrane,go:0005886,mek,protein,,mek1,uniprot,q05524,plasma membrane,go:0005886,positive,d,phosphorylation,,8505c,adenocarcinoma,,human,['41'],nan,nan,"eleven human thyroid cancer-derived cell lines were grown in 10% fbs medium and studied for mek and erk activation: two cell lines without known mapk pathway genetic alteration, one with a ret/ptc rearrangement, two with a ras activating point mutation, and five with the brafv600e mutation. protein expression levels were assayed by immunoblot for the brafv600e mutation, phosphorylated mek (p-mek), total mek1 (t-mek1), phosphorylated erk (p-erk), total erk (t-erk) and gapdh. graphs represent subsequent quantification of p-mek/t-mek1 and p-erk/t-erk ratios. the black star on the upper graph indicates that the quantification of p-mek/t-mek1 was not done in the hth74 cell line due to the loss of t-mek1 expression. however, mek2 expression was secondary assessed and is preserved explaining the p-mek band (data not shown).",pmc5599027,1,10,9,1,19
16,braf,protein,,braf,uniprot,q02533,plasma membrane,go:0005886,mek,protein,,mek1,uniprot,p00775,plasma membrane,go:0005886,positive,d,dimerization,,,b-cell,,vein,['75'],nan,nan,"surprisingly, other mutations were found to render braf inactive (davies et al., 2002). the biochemical analysis of these “kinase-impaired” mutations revealed that although they reduce braf's enzymatic activity, braf still activates mek through dimerization with craf in a ras dependent manner (wan et al., 2004; garnett et al., 2005). confirming earlier studies (weber et al., 2001), it is now well established that raf kinases homo and hetero-dimerize partly in a ras dependent manner. importantly, these interactions can impact on the response to inhibitors of braf. thereby, inhibitor-binding triggers dimerization and in the presence of (hyper)-active ras, instead of pathway-inhibition, this leads to the so called “paradoxical” pathway-activation through craf (wan et al., 2004; garnett et al., 2005; hatzivassiliou et al., 2010; heidorn et al., 2010; poulikakos et al., 2011). elucidation of this complex mechanism has proven valuable in the understanding of some of the side effects that braf inhibitors produce in patients (see below).",pmc4846800,1,10,9,1,19
